Healthcare / Drug Manufacturers - Specialty & GenericBSE
$1141.55
-17.85 (-1.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $81.9M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
65/100
B
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.0B
P/E
14.5x
↓EV/EBITDA
10.0x
↓ROE
17.6%
↑Gross Margin
80.8%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+7.4%
FCF CAGR
-5.0%
FCF margin
7.6%
FCF / Net income
0.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.69B · net income $347.4M · FCF $128.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.69B | $1.69B | $1.52B | $1.42B | $1.36B |
| Net Income | $347.4M | $347.4M | $320.6M | $259.8M | $246.1M |
| EBITDA | $500.9M | $500.9M | $471.1M | $377.5M | $354.2M |
| EPS | — | — | 72.65 | 58.86 | 53.90 |
| Gross Margin | 80.8% | 80.8% | 80.4% | 78.0% | 75.2% |
| Operating Margin | 24.1% | 24.1% | 24.8% | 21.7% | 20.6% |
| Net Margin | 20.6% | 20.6% | 21.1% | 18.3% | 18.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | — | 0.02 |
| Current Ratio | 4.11 | 4.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $128.0M | $128.0M | $81.9M | $55.7M | $149.5M |
| Returns | |||||
| ROE | 17.6% | 17.6% | 18.7% | 17.9% | 20.1% |
| Valuation | |||||
| P/E | 14.50 | 14.50 | 14.39 | 12.66 | 12.51 |
| EV/EBITDA | 10.00 | 10.00 | 9.72 | 8.61 | 8.67 |
| P/B | 2.56 | 2.56 | 2.69 | 2.27 | 2.51 |
| Growth & Yield | |||||
| Revenue Growth | 11.2% | 11.2% | 7.1% | 4.0% | — |
| EPS Growth | — | — | 23.4% | 9.2% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.6%
Start / end P/E
n/dx → n/dx
EPS bridge
72.65 → n/d
Residual
-3.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.